Sandip Kuikel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sandip Kuikel has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Aman Mishra
Tribhuvan University Institute of Medicine Maharajgunj Medical Campus Kathmandu, Bagmati Province, Nepal
4 shared publications - Nibesh Pathak
Maharajgunj Medical Campus, Institute of Medicine, Maharajgunj, Kathmandu, Nepal
3 shared publications - Sanjeev Kharel
Maharajgunj Medical Campus, Institute of Medicine, Maharajgunj, Kathmandu, Nepal
3 shared publications - Suman Rimal
Department of Internal Medicine Tribhuvan University Institute of Medicine Kathmandu Nepal
3 shared publications - Aakash Mishra
Kathmandu Medical College Teaching Hospital Kathmandu Nepal
2 shared publications Amit Sharma Nepal
Tribhuvan University Institute of Medicine Maharajgunj Medical Campus Kathmandu, Bagmati Province, Nepal
2 shared publications
Latest Publications
- Open Access
- 1 June 2024
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2024 (6) , omae055
Severe and rapidly changing hypophosphatemia in cannabinoid hyperemesis syndrome: a case report
The increasing prevalence of cannabis worldwide requires awareness of a potential, less recognized, paradoxical entity, the cannabinoid hyperemesis syndrome (CHS). This includes cyclic episodes of nausea, vomiting, and compulsive hot water bathing for alleviation in individuals with chronic cannabis use. An 18-year-old male with daily and prolonged cannabis use has excessive nausea and vomiting, is diagnosed with CHS, and is further complicated by severe and rapidly fluctuating hypophosphatemia. He was successfully managed with intravenous (IV) antiemetic (metoclopramide) and IV normal saline in the emergency department. Hypophosphatemia was treated with IV phosphorous. Although hypophosphatemia in CHS is a rare encounter, the authors share their experience to promote broader recognition and insight into successful management.
- 1 June 2024
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2024 (6) , omae055
Open AccessSevere and rapidly changing hypophosphatemia in cannabinoid hyperemesis syndrome: a case report
The increasing prevalence of cannabis worldwide requires awareness of a potential, less recognized, paradoxical entity, the cannabinoid hyperemesis syndrome (CHS). This includes cyclic episodes of nausea, vomiting, and compulsive hot water bathing for alleviation in individuals with chronic cannabis use. An 18-year-old male with daily and prolonged cannabis use has excessive nausea and vomiting, is diagnosed with CHS, and is further complicated by severe and rapidly fluctuating hypophosphatemia. He was successfully managed with intravenous (IV) antiemetic (metoclopramide) and IV normal saline in the emergency department. Hypophosphatemia was treated with IV phosphorous. Although hypophosphatemia in CHS is a rare encounter, the authors share their experience to promote broader recognition and insight into successful management.
- Open Access
- 29 April 2024
- Published by Wiley
Systemic Lupus Erythematosus Associated with Erythema Multiforme : A Rare Case Report of Rowell’s Syndrome
Systemic Lupus Erythematosus Associated with Erythema Multiforme : A Rare Case Report of Rowell’s Syndrome
- 29 April 2024
- Published by Wiley
Open AccessSystemic Lupus Erythematosus Associated with Erythema Multiforme : A Rare Case Report of Rowell’s Syndrome
Systemic Lupus Erythematosus Associated with Erythema Multiforme : A Rare Case Report of Rowell’s Syndrome
- Open Access
- 26 March 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (4) , e8677
Systemic lupus erythematosus associated with erythema multiforme: A rare case report of Rowell's syndrome
Key Clinical Message: Although it is very uncommon, SLE may initially present with recurrent episodes of EM‐like rash. Despite the various possibilities underlying their association, prompt identification, and treatment of SLE in patients presenting with EM is important to prevent death or serious organ damage. Rowell's syndrome (RS) is an uncommon presentation of systemic lupus erythematosus (SLE) with erythema multiforme (EM)‐like lesions associated with specific serological changes, including positive rheumatoid factor (RF), speckled antinuclear antibody (ANA), positive rheumatoid factor, or anti‐La antibodies in the serum. Our case, a 41‐year‐old male, presented with features of EM. Upon investigation, we identified underlying systemic lupus erythematosus, marking a rare instance of SLE presenting for the first time as EM. Classical or true EM is precipitated by trigger factors such as infective agents like the herpes simplex virus, Mycoplasma pneumoniae, drugs like anticonvulsants, antibiotics, and non‐steroid anti‐inflammatory drugs, any underlying malignancy, or connective tissue disorders, and is not associated with any specific serological abnormalities. EM cases associated with LE lesions where an EM trigger factor is missing are considered an RS diagnostic criterion. In this case report, the importance of considering SLE in patients presenting initially with recurrent episodes of EM‐like rash is emphasized. RS should be considered, especially when there is no evidence of triggering factors. Early diagnosis and prompt treatment of SLE are crucial to preventing death and irreversible organ damage.
- 26 March 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (4) , e8677
Open AccessSystemic lupus erythematosus associated with erythema multiforme: A rare case report of Rowell's syndrome
Key Clinical Message: Although it is very uncommon, SLE may initially present with recurrent episodes of EM‐like rash. Despite the various possibilities underlying their association, prompt identification, and treatment of SLE in patients presenting with EM is important to prevent death or serious organ damage. Rowell's syndrome (RS) is an uncommon presentation of systemic lupus erythematosus (SLE) with erythema multiforme (EM)‐like lesions associated with specific serological changes, including positive rheumatoid factor (RF), speckled antinuclear antibody (ANA), positive rheumatoid factor, or anti‐La antibodies in the serum. Our case, a 41‐year‐old male, presented with features of EM. Upon investigation, we identified underlying systemic lupus erythematosus, marking a rare instance of SLE presenting for the first time as EM. Classical or true EM is precipitated by trigger factors such as infective agents like the herpes simplex virus, Mycoplasma pneumoniae, drugs like anticonvulsants, antibiotics, and non‐steroid anti‐inflammatory drugs, any underlying malignancy, or connective tissue disorders, and is not associated with any specific serological abnormalities. EM cases associated with LE lesions where an EM trigger factor is missing are considered an RS diagnostic criterion. In this case report, the importance of considering SLE in patients presenting initially with recurrent episodes of EM‐like rash is emphasized. RS should be considered, especially when there is no evidence of triggering factors. Early diagnosis and prompt treatment of SLE are crucial to preventing death and irreversible organ damage.
- Open Access
- 5 March 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (4) , 1997-2003
Study of caudal ropivacaine with or without dexmedetomidine for postoperative analgesia in paediatric genitourinary infraumbilical surgery: a double-blinded randomized controlled trial
Various studies have described the use of Dexmedetomidine with local anaesthetic drugs in caudal blocks for the management of postoperative pain in children. This study was designed to determine the analgesic effect of caudal Dexmedetomidine with Ropivacaine in paediatric genitourinary infraumbilical surgeries. Postoperative analgesic effects of caudal Ropivacaine with or without Dexmedetomidine in paediatric genitourinary infraumbilical were evaluated. This study was a prospective, interventional, comparative study conducted after ethical approval from the institute. Informed expressed consent was taken from each patient’s guardians. The sample size was calculated to be 31 in each group. The two groups were randomly assigned and the intervention involved caudal epidural injection with either Ropivacaine combined with Dexmedetomidine or Ropivacaine with Normal Saline. Children receiving Ropivacaine with Dexmedetomidine had a significantly prolonged duration of analgesia compared to those receiving Ropivacaine alone (840.35 ± 149.97 vs. 412.90 ± 93.46 min, P < 0.001). Postoperative rFLACC scores were consistently lower in the Dexmedetomidine group, indicating better pain control (P < 0.05 at 6, 12, and 24 h). Total analgesic consumption was lower in the Dexmedetomidine group (500.67 ± 212.92 vs. 741.75 ± 268.06 mg, P < 0.01). No significant differences in adverse effects were observed between the groups. The addition of Dexmedetomidine to Ropivacaine in caudal epidural significantly prolongs analgesia, improves pain control, and reduces analgesic consumption in paediatric genitourinary infraumbilical surgeries.
- 5 March 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (4) , 1997-2003
Open AccessStudy of caudal ropivacaine with or without dexmedetomidine for postoperative analgesia in paediatric genitourinary infraumbilical surgery: a double-blinded randomized controlled trial
Various studies have described the use of Dexmedetomidine with local anaesthetic drugs in caudal blocks for the management of postoperative pain in children. This study was designed to determine the analgesic effect of caudal Dexmedetomidine with Ropivacaine in paediatric genitourinary infraumbilical surgeries. Postoperative analgesic effects of caudal Ropivacaine with or without Dexmedetomidine in paediatric genitourinary infraumbilical were evaluated. This study was a prospective, interventional, comparative study conducted after ethical approval from the institute. Informed expressed consent was taken from each patient’s guardians. The sample size was calculated to be 31 in each group. The two groups were randomly assigned and the intervention involved caudal epidural injection with either Ropivacaine combined with Dexmedetomidine or Ropivacaine with Normal Saline. Children receiving Ropivacaine with Dexmedetomidine had a significantly prolonged duration of analgesia compared to those receiving Ropivacaine alone (840.35 ± 149.97 vs. 412.90 ± 93.46 min, P < 0.001). Postoperative rFLACC scores were consistently lower in the Dexmedetomidine group, indicating better pain control (P < 0.05 at 6, 12, and 24 h). Total analgesic consumption was lower in the Dexmedetomidine group (500.67 ± 212.92 vs. 741.75 ± 268.06 mg, P < 0.01). No significant differences in adverse effects were observed between the groups. The addition of Dexmedetomidine to Ropivacaine in caudal epidural significantly prolongs analgesia, improves pain control, and reduces analgesic consumption in paediatric genitourinary infraumbilical surgeries.
- Open Access
- 27 June 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (6) , e1371
Prevalence and clinical impact of anemia in patients diagnosed with chronic obstructive pulmonary disease: A cross‐sectional study
Background and Aims: Unlike classically described polycythemia, anemia is found to be more prevalent in patients with chronic obstructive pulmonary disease (COPD). Anemia increases the cost of hospital stay and causes an increased risk of adverse outcomes including death in COPD patients. This study was done to find the prevalence of anemia in COPD patients, the factors associated, and the outcomes of anemic COPD.Methods: It was a quantitative, descriptive‐analytical, and cross‐sectional study conducted in Tribhuvan University Teaching Hospital's medical wards and the Emergency Room from September 2019 to September 2020. A simple random sampling method was used. Clinical information was obtained, and patients were followed up 3 months after discharge to document the number of exacerbations and deaths if present.Results: The patients in our study had a mean age of 70.80 ± 11.16 years. Most were female. Most (85.5%) had a history of exposure to firewood smoke. Twenty‐three percent of the patients had anemia and these patients had significantly greater mortality 3 months postdischarge. Middle‐old and old were more likely to have anemia with odds ratio (OR) of 2.55 (confidence interval [CI]: 0.48–13.5) and 13.6 (CI: 1.12–24.2), respectively. Current smokers had less likelihood of having anemia (OR: 0.05, CI: 0.006–0.49). Multivariate analysis showed that age, sex, and smoking status were significant determinants of anemia in COPD. There was no association between anemia and duration of hospital stay. However, mortality was higher at 3 months in COPD patients with anemia (p < 0.001).Conclusion: In COPD patients, anemia is prevalent comorbidity that is significantly linked to higher mortality but not to exacerbations. It is unknown, though, if treating anemia in COPD patients will affect the patient's outcome. Additional research in this area may be possible.
- 27 June 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (6) , e1371
Open AccessPrevalence and clinical impact of anemia in patients diagnosed with chronic obstructive pulmonary disease: A cross‐sectional study
Background and Aims: Unlike classically described polycythemia, anemia is found to be more prevalent in patients with chronic obstructive pulmonary disease (COPD). Anemia increases the cost of hospital stay and causes an increased risk of adverse outcomes including death in COPD patients. This study was done to find the prevalence of anemia in COPD patients, the factors associated, and the outcomes of anemic COPD.Methods: It was a quantitative, descriptive‐analytical, and cross‐sectional study conducted in Tribhuvan University Teaching Hospital's medical wards and the Emergency Room from September 2019 to September 2020. A simple random sampling method was used. Clinical information was obtained, and patients were followed up 3 months after discharge to document the number of exacerbations and deaths if present.Results: The patients in our study had a mean age of 70.80 ± 11.16 years. Most were female. Most (85.5%) had a history of exposure to firewood smoke. Twenty‐three percent of the patients had anemia and these patients had significantly greater mortality 3 months postdischarge. Middle‐old and old were more likely to have anemia with odds ratio (OR) of 2.55 (confidence interval [CI]: 0.48–13.5) and 13.6 (CI: 1.12–24.2), respectively. Current smokers had less likelihood of having anemia (OR: 0.05, CI: 0.006–0.49). Multivariate analysis showed that age, sex, and smoking status were significant determinants of anemia in COPD. There was no association between anemia and duration of hospital stay. However, mortality was higher at 3 months in COPD patients with anemia (p < 0.001).Conclusion: In COPD patients, anemia is prevalent comorbidity that is significantly linked to higher mortality but not to exacerbations. It is unknown, though, if treating anemia in COPD patients will affect the patient's outcome. Additional research in this area may be possible.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 11
Haloperidol-induced sudden cardiac arrest in a recently detected HIV and hepatitis C patient: A unique case report
We herein described a case of a 45-year-old male recently detected with HIV and Hepatitis C who presented with signs of sepsis, developed delirium, and received haloperidol. Surprisingly, 10 min after intravenous administration, the patient developed Torsades de pointes and required immediate resuscitation. The report discusses the limited instances of cardiac arrest linked to haloperidol use, despite its generally perceived safety. The patient had no apparent risk factors, emphasizing the need for increased caution when administering haloperidol, particularly in critically ill patients with HIV and Hepatitis C.
- 1 January 2023
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 11
Open AccessHaloperidol-induced sudden cardiac arrest in a recently detected HIV and hepatitis C patient: A unique case report
We herein described a case of a 45-year-old male recently detected with HIV and Hepatitis C who presented with signs of sepsis, developed delirium, and received haloperidol. Surprisingly, 10 min after intravenous administration, the patient developed Torsades de pointes and required immediate resuscitation. The report discusses the limited instances of cardiac arrest linked to haloperidol use, despite its generally perceived safety. The patient had no apparent risk factors, emphasizing the need for increased caution when administering haloperidol, particularly in critically ill patients with HIV and Hepatitis C.
- Open Access
- 26 December 2022
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 17 (2) , 73-79
Safety and efficacy of prophylactic anticoagulation versus therapeutic anticoagulation in hospital‐admitted COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials
Background: COVID‐19 disease‐related coagulopathy and thromboembolic complication, an important aspect of the disease pathophysiology, are frequent and associated with poor outcomes, particularly significant in hospitalized patients. Undoubtedly, anticoagulation forms a cornerstone for the management of hospitalized COVID‐19 patients, but the appropriate dosing has been inconclusive and a subject of research. We aim to review existing literature and compare safety and efficacy outcomes of prophylactic and therapeutic dose anticoagulation in such patients.Methods: We did a systematic review and meta‐analysis to compare the efficacy and safety of prophylactic dose anticoagulation when compared with therapeutic dosing in hospitalized COVID‐19 patients. We searched PubMed, Google Scholar, EMBASE and COCHRANE databases from 2019 to 2021, without any restriction by language. We screened records, extracted data and assessed the risk of bias in the studies. RCTs that directly compare therapeutic and prophylactic anticoagulants dosing and are not placebo‐controlled trials were included. Analyses of data were conducted using the Mantel–Haenszel random‐effects model (DerSimonian–Laird analysis). The study is registered with PROSPERO (CRD42021265948).Results: We included three studies in the final quantitative analysis. The incidence of thromboembolic events in therapeutic anticoagulation was lower in comparison with prophylactic anticoagulation in hospitalized COVID‐19 patients and reached statistical significance [RR 1·45, 95% CI (1.07, 1.97) I2 –0%], whereas major bleeding as an adverse event was found lower in prophylactic anticoagulation in comparison with therapeutic anticoagulation that was statistically significant [RR 0·42, 95% CI(0.19, 0.93) I2 –0%].Conclusion: Our study shows that therapeutic dose anticoagulation is more effective in preventing thromboembolic events than prophylactic dose but significantly increases the risk of major bleeding as an adverse event. So, the risk–benefit ratio must be considered while using either of them.
- 26 December 2022
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 17 (2) , 73-79
Open AccessSafety and efficacy of prophylactic anticoagulation versus therapeutic anticoagulation in hospital‐admitted COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials
Background: COVID‐19 disease‐related coagulopathy and thromboembolic complication, an important aspect of the disease pathophysiology, are frequent and associated with poor outcomes, particularly significant in hospitalized patients. Undoubtedly, anticoagulation forms a cornerstone for the management of hospitalized COVID‐19 patients, but the appropriate dosing has been inconclusive and a subject of research. We aim to review existing literature and compare safety and efficacy outcomes of prophylactic and therapeutic dose anticoagulation in such patients.Methods: We did a systematic review and meta‐analysis to compare the efficacy and safety of prophylactic dose anticoagulation when compared with therapeutic dosing in hospitalized COVID‐19 patients. We searched PubMed, Google Scholar, EMBASE and COCHRANE databases from 2019 to 2021, without any restriction by language. We screened records, extracted data and assessed the risk of bias in the studies. RCTs that directly compare therapeutic and prophylactic anticoagulants dosing and are not placebo‐controlled trials were included. Analyses of data were conducted using the Mantel–Haenszel random‐effects model (DerSimonian–Laird analysis). The study is registered with PROSPERO (CRD42021265948).Results: We included three studies in the final quantitative analysis. The incidence of thromboembolic events in therapeutic anticoagulation was lower in comparison with prophylactic anticoagulation in hospitalized COVID‐19 patients and reached statistical significance [RR 1·45, 95% CI (1.07, 1.97) I2 –0%], whereas major bleeding as an adverse event was found lower in prophylactic anticoagulation in comparison with therapeutic anticoagulation that was statistically significant [RR 0·42, 95% CI(0.19, 0.93) I2 –0%].Conclusion: Our study shows that therapeutic dose anticoagulation is more effective in preventing thromboembolic events than prophylactic dose but significantly increases the risk of major bleeding as an adverse event. So, the risk–benefit ratio must be considered while using either of them.
- Open Access
- 1 December 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (2) , 643-646
Radiologic finding of intraosseous gas: A rare case of emphysematous osteomyelitis of the foot
- 1 December 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (2) , 643-646
Open AccessRadiologic finding of intraosseous gas: A rare case of emphysematous osteomyelitis of the foot
- Open Access
- 5 October 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4761-4765
A rare incidental finding of an isolated S1 butterfly vertebra: A case report
- 5 October 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4761-4765
Open AccessA rare incidental finding of an isolated S1 butterfly vertebra: A case report
- Open Access
- 27 September 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 82, 104765
A case of huge ovarian cyst in second trimester: A rare case report
Large cystic masses are rare in pregnancy. Corpus luteum cysts and theca lutein cysts are common are most common among all. Ovarian masses are usually discovered as an incidental finding during routine obstetric ultrasonography. Management depends upon the size of the mass, and the symptoms produced by the mass. Our case describes an incidental finding of a large ovarian cyst during the second trimester, in a 24-year-old female patient. Per abdominal examination revealed a huge mass in the epigastrium, left hypogastrium, and left lumbar region, along with 20 weeks sized uterus. Ultrasonography revealed a cystic mass of 11.9 cm × 11.7 cm X 15.9 cm, with multiple septations and cystic areas. After other baseline investigations, she was planned for surgical removal of the mass. Upon histopathologic examination after surgical excision, the mass was found to be mucinous cystadenoma. Large ovarian masses are uncommon during pregnancy. The most common complications of ovarian masses in pregnancy are torsion, rupture, infection, or malpresentation of the fetus. Surgical management can be done if the mass presents with acute symptoms like torsion, or if the size of the mass is greater than 5 cm. Non-obstetric surgery for cyst removal can be done electively during the second trimester, or irrespective of the period of gestation if there are acute symptoms. Large ovarian masses are usually rare during pregnancy. It is necessary to properly evaluate the case of ovarian masses during pregnancy, to decide the appropriate line of management.
- 27 September 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 82, 104765
Open AccessA case of huge ovarian cyst in second trimester: A rare case report
Large cystic masses are rare in pregnancy. Corpus luteum cysts and theca lutein cysts are common are most common among all. Ovarian masses are usually discovered as an incidental finding during routine obstetric ultrasonography. Management depends upon the size of the mass, and the symptoms produced by the mass. Our case describes an incidental finding of a large ovarian cyst during the second trimester, in a 24-year-old female patient. Per abdominal examination revealed a huge mass in the epigastrium, left hypogastrium, and left lumbar region, along with 20 weeks sized uterus. Ultrasonography revealed a cystic mass of 11.9 cm × 11.7 cm X 15.9 cm, with multiple septations and cystic areas. After other baseline investigations, she was planned for surgical removal of the mass. Upon histopathologic examination after surgical excision, the mass was found to be mucinous cystadenoma. Large ovarian masses are uncommon during pregnancy. The most common complications of ovarian masses in pregnancy are torsion, rupture, infection, or malpresentation of the fetus. Surgical management can be done if the mass presents with acute symptoms like torsion, or if the size of the mass is greater than 5 cm. Non-obstetric surgery for cyst removal can be done electively during the second trimester, or irrespective of the period of gestation if there are acute symptoms. Large ovarian masses are usually rare during pregnancy. It is necessary to properly evaluate the case of ovarian masses during pregnancy, to decide the appropriate line of management.